CTOs on the Move

Aldeyra Therapeutics, Inc

www.aldeyra.com

 
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.aldeyra.com
  • 15 New England Executive Park
    Burlington, MA USA 01803
  • Phone: 781.270.0630

Executives

Name Title Contact Details

Funding

Aldeyra Therapeutics, Inc raised $60M on 03/26/2019
Aldeyra Therapeutics, Inc raised $74.7M on 01/20/2021
Aldeyra Therapeutics, Inc raised $125M on 04/28/2021

Similar Companies

BICO

We are industry-leading experts in Bio Convergence. By combining the power of biology, engineering and computer science, we create the future of health. We extend the boundaries of what`s possible to give people better and healthier lives. Products from the BICO Group are trusted by more than 2,00 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 1800 publications. BICO is creating the future of health. Visit bico.com to learn more. BICO is listed on the Nasdaq Stockholm Main Market under BICO.

ICON Laboratories

ICON Laboratories is a Farmingdale, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VivoQuest

VivoQuest, Inc. is a Valley Cottage, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IMIDomics

IMIDomics is a biotechnology company focused on Patient-Centric drug discovery for immune-mediated inflammatory diseases (IMIDs). Our goal is to discover new and impactful IMID drugs by focusing on carefully selected patients, and stratifying populations to identify those most likely to respond. IMIDomics is powered by a unique Clinical Discovery EngineTM, which integrates and analyzes proprietary clinical, epidemiological and patient-derived biomolecular datasets, generated in partnership with the Vall d`Hebron Institute of Research, to establish a deeper understanding of IMID diseases. By doing so, IMIDomics has identified previously unrecognized targets, six of which have been selected for development. By relying on access to well-defined patients and their clinically relevant samples, IMIDomics enhances the probability of successful IMID drug discovery and development for those in need.

L7 Informatics

L7 Informatics provides software and services that enable synchronized solutions for science + health. L7`s novel L7|ESP is a scientific process and data management (SPDM) solution that enables life science and healthcare companies to connect people, processes, and systems to accelerate discoveries and drive precision healthcare.